Day 1Wednesday, 23 April 2025 - CT (China Time, GMT+08:00)

Location: Pudong Ballroom 1-3

Location: Pudong Ballroom 1-3

This keynote panel brings together senior leaders from global biotech MNCs to examine China’s expanding role in the global biotech ecosystem. The discussion will focus on strategic opportunities for collaboration, navigating the complexities of China’s market and regulatory landscape, and balancing competition with cooperation to drive innovation.

• How can international biotech companies foster meaningful partnerships with Chinese firms while remaining competitive?
• What shifts in regulatory frameworks and investment priorities are needed to facilitate seamless cross-border collaborations?
• How can global companies leverage China’s market dynamics to drive breakthroughs and maintain a competitive edge?
  
  

Location: Pudong Ballroom 1-3

This panel will showcase how China’s leading biotech firms are pioneering scientific and technological breakthroughs, transforming R&D models, and shaping the future of medicine. It will explore how homegrown innovation, government policies, and evolving collaborations within China are enabling the rapid development of next-generation therapies in areas such as CRISPR, cell and gene therapy, RNA-based treatments, and AI-driven drug discovery.

• How is China’s biotech sector evolving beyond being a fast follower to becoming a global leader in scientific innovation?

• What unique R&D models, funding mechanisms, and government-backed initiatives are accelerating biotech innovation in China?

• How are Chinese companies advancing the next wave of breakthrough therapies, and what lessons can global biotech firms learn from their approach?

• What are the biggest bottlenecks in innovation and commercialization, and how is the ecosystem adapting to overcome these challenges?

• In what way are leading global biopharma companies engaging with China’s biotech ecosystem – beyond traditional licensing deals?

Location: Pudong Ballroom 1-3

As China’s life sciences sector continues to evolve in 2025, companies must navigate shifting regulations, dynamic dealmaking trends, and new cross-border complexities. This panel brings together industry leaders and legal experts to explore the most pressing risks and emerging opportunities shaping the market.

• The trajectory of life sciences transactions in 2025: What’s driving deals, and where is the momentum?

• The future of out-licensing and NewCo deals—temporary surge or long-term shift?

• Navigating risks in an evolving market from an in-house counsel’s perspective.

• Key considerations for deal sourcing between major China and U.S. pharma companies.

• The impact of the DOJ’s bulk data transfer rule and the Biosecure Act on global investment strategies.

• Cross-border partnerships: How shifting policies and regulatory scrutiny are reshaping China-U.S. biotech collaborations.

• Key enforcement trends, regulatory expectations, and risk mitigation strategies for biotech and pharmaceutical companies operating in China.

Location: Pudong Ballroom 1-3

In today's rapidly evolving life sciences sector, companies face intricate challenges and opportunities in collaborations, cross-border transactions, and fundraising. This session explores cutting-edge strategies for navigating these complex landscapes. Industry experts will share insights on structuring international partnerships, managing cross-border M&A, and optimizing fundraising approaches for life sciences companies at various stages of growth.

• What are the latest trends in cross-border collaborations and licensing agreements in the life sciences sector, and how can companies structure deals to maximize value while minimizing risks?

• How are regulatory changes and geopolitical factors impacting cross-border M&A activities and fundraising strategies in the life sciences industry?

• What strategies are emerging for successful fundraising in the current market, from early-stage financing to IPOs, and how can companies navigate the challenges of each stage?

Location: Pudong Ballroom 1-3

Amid economic uncertainties and a tightening investment landscape, many are asking whether we are in a prolonged "investment winter" or if signs of a thaw are emerging. However, strategic partnerships, licensing deals, and cross-border collaborations are emerging as critical drivers of innovation. This panel will bring together investors, multinational pharma leaders, and biotech executives to discuss how capital is flowing in new ways and where the next wave of biotech growth will come from.

• Analysis of the factors contributing to the slowdown in biotech funding, including macroeconomic conditions, geopolitical influences, and changing investor sentiments. 

• How multinational pharma companies are filling funding gaps through licensing deals, joint ventures, and R&D collaborations, particularly in China.

• Identifying areas within life sciences that continue to attract investor interest, such as AI-driven drug discovery, gene editing, and next-generation therapeutics. 

• Strategies for biotech companies to position themselves favourably when the investment climate improves, including a focus on robust data, clear value propositions, and strong partnerships. 

• Insights into how investment trends differ across regions, with a special focus on the Chinese market's role in driving innovation and funding in the life sciences sector.